Trials / Terminated
TerminatedNCT04564417
First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors
Phase I Dose Escalation and Dose Expansion, International, Multicenter Study of W0180 as Single Agent and in Combination With Pembrolizumab (Anti-PD-1) in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Pierre Fabre Medicament · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study will be to determine the Maximum Tolerated Dose (MTD) and describe dose-limiting toxicities (DLTs) of W0180 given as monotherapy and in combination with pembrolizumab (anti-PD-1).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | W0180 | Participants will receive W0180 in a 21-day cycle. |
| DRUG | Pembrolizumab | Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) in a 21-day cycle. |
Timeline
- Start date
- 2020-09-08
- Primary completion
- 2023-12-19
- Completion
- 2023-12-19
- First posted
- 2020-09-25
- Last updated
- 2024-01-31
Locations
5 sites across 2 countries: France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04564417. Inclusion in this directory is not an endorsement.